Abstract
Game theory-inspired deep learning using a generative adversarial network provides an environment to competitively interact and accomplish a goal. In the context of medical imaging, most work has focused on achieving single tasks such as improving image resolution, segmenting images, and correcting motion artifacts. We present a dual-objective adversarial learning framework that simultaneously (1) reconstructs higher quality brain magnetic resonance images (MRIs) that (2) retain disease-specific imaging features critical for predicting progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). We obtained 3-Tesla, T1-weighted brain MRIs of participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI, N=342) and the National Alzheimer’s Coordinating Center (NACC, N=190) datasets. We simulated MRIs with missing data by removing 50% of sagittal slices from the original scans (i.e., diced scans). The generator was trained to reconstruct brain MRIs using the diced scans as input. We introduced a classifier into the GAN architecture to discriminate between stable (i.e., sMCI) and progressive MCI (i.e., pMCI) based on the generated images to facilitate encoding of AD-related information during reconstruction. The framework was trained using ADNI data and externally validated on NACC data. In the NACC cohort, generated images had better image quality than the diced scans (SSIM: 0.553 ± 0.116 versus 0.348 ± 0.108). Furthermore, a classifier utilizing the generated images distinguished pMCI from sMCI more accurately than with the diced scans (F1-score: 0.634 ± 0.019 versus 0.573 ± 0.028). Competitive deep learning has potential to facilitate disease-oriented image reconstruction in those at risk of developing Alzheimer’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Karen Toffler Charitable Trust, the National Institute of Diabetes and Digestive and Kidney Diseases Diabetic Complications Consortium grant (Subaward:32307-93 from U24-DK115255), a Strategically Focused Research Network (SFRN) Center (20SFRN35460031) from the American Heart Association, and the National Institutes of Health (RF1-AG062109, U19-AG068753, R01-HL159620, R21-CA253498, and R43-DK134273).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.